Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795574 | 1.00 | MAPT (0.49) | MAPTSMN1; SMN2TP53HDAC6TSHR | |
| SCHEMBL693496 | 0.83 | KCNQ2 (0.44) | MAPTHDAC6KCNQ2 | |
| SCHEMBL30795656 | 0.83 | KCNQ2 (0.44) | MAPTHDAC6KCNQ2 | |
| SCHEMBL30794396 | 0.81 | KCNQ2 (0.62) | HDAC6KCNQ2 | |
| SCHEMBL694023 | 0.81 | KCNQ2 (0.62) | HDAC6KCNQ2 | |
| SCHEMBL30795847 | 0.79 | PTGER4 (0.46) | TP53HDAC6KCNQ2 | |
| SCHEMBL2680089 | 0.79 | PTGER4 (0.46) | TP53HDAC6KCNQ2 | |
| SCHEMBL2680430 | 0.77 | PTGER4 (0.41) | TP53HDAC6KCNQ2 | |
| SCHEMBL30796044 | 0.77 | PTGER4 (0.41) | TP53HDAC6KCNQ2 | |
| SCHEMBL2679534 | 0.76 | GRM1 (0.51) | HDAC6KDRPDGFRBKCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| EP-2421863-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122064-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNQ1, KCNQ2, KCNQ5 | MAPT 3190/4885SMN1; SMN2 3133/4885TP53 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.